Navigation Links
New Melanoma Drug May Extend Survival
Date:6/25/2012

MONDAY, June 25 (HealthDay News) -- New research suggests that a new drug does a better job of combating advanced skin cancer in melanoma patients than chemotherapy.

However, patients typically still got worse after only a few months on the drug.

The drug, called dabrafenib, blocks a signaling protein and is used to treat melanomas with a specific genetic mutation. About half of melanoma patients have this mutation.

In a phase 3 trial funded by the drug's maker, GlaxoSmithKline, an international group of researchers led by Dr. Axel Hauschild of the Schleswig-Holstein University Hospital in Kiel, Germany, gave dabrafenib or the most common existing treatment, dacarbazine (DTIC-Dome), to 250 patients with spreading or inoperable melanoma. About half responded partially (47 percent) or fully (3 percent) to dabrafenib; the response rate among the dacarbazine group was just 6 percent.

Those who took the new drug survived for an average of 5.1 months without getting worse; 2.7 percent of those treated with the existing drug did the same.

The study authors report that the new drug had few side effects, and those related to the skin appeared to be less severe than in patients on a similar drug called vemurafenib (Zelboraf). That drug is now available in the United States.

It's not clear if the drug will affect overall survival rates. "This trial is good news for our patients with metastatic melanoma. Competition in the field is appreciated since it accelerates new clinical trials, particularly in the combinational setting," Hauschild said in a news release from The Lancet, which published the study online June 25.

"This trial is a major step forward in the run for an improvement of the survival for this disease, which was thought to be untreatable for decades," he added.

Dr. Vernon K. Sondak, chair of the department of cutaneous oncology at the Moffitt Cancer Center in Tampa, said treatments for melanoma have been lacking. New so-called "targeted" drugs like dabrafenib have shown promise, he added, "but all these targeted therapies have a weakness, and that is the eventual development of resistance in the tumor cells."

Still, the research into various drugs "opens up new possibilities for combination therapies that may be even more effective, potentially without causing increased side effects," he said.

As for cost, Sondak said melanoma treatments have been so expensive that health agencies in some countries have refused to pay for them.

More information

For more about melanoma, try the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Vernon K. Sondak, M.D., surgeon and chair, department of cutaneous Oncology, Moffitt Cancer Center, Tampa; June 25, 2012, The Lancet, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Surgery Rates Rising for Non-Melanoma Skin Cancer: Study
2. Moffitt Cancer Center researchers working at frontiers of melanoma research
3. Women More Likely to Survive Melanoma Than Men: Study
4. Scientists Map Melanomas Genome
5. Two-Drug Combo May Be Safe for Melanoma Treatment
6. Melanoma a Big Threat to Older Men
7. Fish shed light on human melanoma
8. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
9. Healthy Behaviors Extend Life After Cancer, Experts Say
10. Exercise and a healthy diet of fruits and vegetables extends life expectancy in women in their 70s
11. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Melanoma Drug May Extend Survival
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that ... dermaka cream can be incorporated into the post-surgical treatment plans of a variety of ... , dermaka cream is very effective for bruising and causes a rapid resolution of ...
(Date:6/24/2016)... New York (PRWEB) , ... June 24, 2016 , ... ... marijuana patients optimize the ingestion of their medication by matching users with high quality ... users to compare pieces with no commitment. , Inhale was founded by two brothers, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology: